Research & Development
Sanofi and Regeneron's Dupixent meets all endpoints in pivotal AFRS study; sBLA accepted for FDA priority review
7 November 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) on Friday announced positive results from the phase 3 LIBERTY-AFRS-AIMS study evaluating Dupixent (dupilumab) ...
MavriX Bio reports first patient dosed in Phase 1/2 trial of MVX-220 for AS
7 November 2025 - Clinical-stage biotechnology company MavriX Bio and AS2Bio, a drug development accelerator established by the Foundation for Angelman Syndrome Therapeutics (FAST), announced on Thurs...
Johnson & Johnson's DARZALEX FASPRO receives US FDA approval
7 November 2025 - Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that it has received approval from the US Food and Drug Administration (FDA) for DARZALEX...
Calico Life Sciences' ABBV-CLS-628S granted US FDA Orphan Drug Designation
6 November 2025 - Calico Life Sciences LLC, a biotechnology company focused on ageing and age-related diseases, founded by Alphabet Inc (NASDAQ:GOOG) and Arthur D. Levinson, announced on Wednesday tha...
Galderma secures US FDA approval for Restylane Lyft to enhance chin profile
5 November 2025 - Dermatology specialist Galderma (SWX:GALD) announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for Restylane Lyft with Lidocaine, expa...
Spinogenix reveals positive SPG302 topline results from Phase 2a study for treatment of ALS
5 November 2025 - Clinical-stage biopharmaceutical company Spinogenix Inc on Tuesday reported positive topline results from its completed Phase 2a study for SPG302 in patients with Amyotrophic Lateral...